Principal Investigator
Gilberto Lopes
Enrollment Status
Open
Clinical Trial ID
Institutional Protocol #
20230915
Clinical Trial Summary
A Phase 1/2 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 in Patients with Advanced NSCLC and Other Solid Tumors (ALKOVE-1)
Phase
Phase I/II
Funding Agency/Sponsor
Industrial
Disease
Thoracic Oncology
Contact Information
Phone Number
305-243-2647